WANG Botai. Clinical effect of tiotropium bromide powder for inhalation combined with N-acetylcysteine effervescent tablets for patients with chronic obstructive pulmonary disease[J]. Journal of Clinical Medicine in Practice, 2020, 24(20): 108-111. DOI: 10.7619/jcmp.202020030
Citation: WANG Botai. Clinical effect of tiotropium bromide powder for inhalation combined with N-acetylcysteine effervescent tablets for patients with chronic obstructive pulmonary disease[J]. Journal of Clinical Medicine in Practice, 2020, 24(20): 108-111. DOI: 10.7619/jcmp.202020030

Clinical effect of tiotropium bromide powder for inhalation combined with N-acetylcysteine effervescent tablets for patients with chronic obstructive pulmonary disease

More Information
  • Received Date: August 02, 2020
  • Available Online: December 21, 2020
  • Published Date: November 12, 2020
  • Objective To explore the effect of tiotropium bromide powder for inhalation combined with N-acetylcysteine(NAC)effervescent tablets on the clinical efficacy and lung function of patients with chronic obstructive pulmonary disease. Methods A total of 86 chronic obstructive pulmonary disease patients in our hospital were divided into control group and observation group, with 43 cases in each group, patients of two groups were given water electrolyte disorder correcting, resolving phlegm and relieving cough oxygen and other conventional treatments, the control group was given tiotropium bromide powder for inhalation on the basis of conventional treatment, the observation group was given tiotropium bromide powder for inhalation and NAC effervescent tablets based on the conventional treatment. Treatment was lasted for 4 weeks. Clinical efficacy, lung function, arterial blood gas related indexes and inflammatory factors were compared between the two groups. Results The total effective rate of the observation group was significantly higher than that in the control group(P<0.05). After treatment, forced expiratory volume in one second(FEV1), ratio of FEV1 to forced vital capacity(FVC)(FEV1/FVC), peak expiratory flow(PEF)and forced vital capacity(VC)were all increased in the two groups, and the above indexes in the observation group were significantly higher than those in the control group(P<0.05). After treatment, arterial partial pressure of oxygen[pa(O2)] and oxygen saturation(SaO2)in the two groups were increased, while partial pressure of carbon dioxide in - artery[pa(CO2)] was decreased, and the observation group had higher levels of pa(O2)and SaO2, and lower pa(CO2)level than the control group(P<0.05). Tumor necrosis factor-α(TNF-α), high sensitive C-reactive protein(hs-CRP)and interleukin-6(IL-6)levels were all decreased after treatment in both groups, and the above indexes in the observation group were all significantly lower than those in the control group(P<0.05). Conclusion Tiotropium bromide powder for inhalation combined with NAC effervescent tablets has a good clinical effect in the treatment of chronic obstructive pulmonary disease, which can improve patients' lung function and relieve inflammatory response.
  • 曹开秀, 李争, 王先敏. 慢性阻塞性肺疾病与衰老调控机制的研究进展[J]. 中华老年医学杂志, 2020, 39(2): 241-244.
    黄骁燕, 余维巍, 刘建. 噻托溴铵喷雾剂对中重度稳定期慢性阻塞性肺疾病患者睡眠质量和肺功能的影响[J]. 中国医师进修杂志, 2018, 41(3): 197-200.
    胡朝阳, 张小红. 固本咳喘片联合噻托溴铵治疗慢性阻塞性肺疾病急性加重期的临床研究[J]. 现代药物与临床, 2019, 21(13): 597-599.
    王发辉, 石慧芳, 林石宁, 等. 噻托溴铵粉雾剂联合沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病急性加重期伴呼吸衰竭的临床研究[J]. 中国临床药理学杂志, 2018, 26(23): 369-371.
    李小丽, 夏玉红, 陈亚飞, 等. 溴己新联合噻托溴铵治疗慢性阻塞性肺疾病稳定期的临床研究[J]. 现代药物与临床, 2020, 45(32): 289-291.
    肖幸, 杨梦晨, 张存泰, 等. 噻托溴铵喷雾剂替换沙美特罗替卡松治疗老年慢性阻塞性肺疾病的临床研究[J]. 中国医院药学杂志, 2019, 24(17): 891-893.
    白春学, 汤彦, 辛建保, 等. 噻托溴铵/奥达特罗治疗中国慢性阻塞性肺疾病患者的有效性和安全性分析[J]. 中华结核和呼吸杂志, 2019, 42(11): 838-844.
    马春兰, 王春茂, 李万成, 等. 噻托溴铵联合N-乙酰半胱氨酸治疗慢性阻塞性肺疾病稳定期的疗效观察[J]. 海南医学, 2018, 29(8): 1072-1075.
    迟玉敏, 邸庆国, 李敏, 等. 乙酰半胱氨酸泡腾片治疗慢性阻塞性肺疾病的临床研究[J]. 中国临床药理学杂志, 2018, 27(13): 475-478.
    江城, 张念, 张燕. 噻托溴铵粉吸入剂治疗慢性阻塞性肺疾病与阻塞性睡眠呼吸暂停重叠综合征36例[J]. 医药导报, 2018, 37(12): 1474-1477.
    符瑜, 吴少敏, 卢海兰, 等. 噻托溴铵联合沙美特罗/丙酸氟替卡松治疗慢性阻塞性肺疾病稳定期患者的临床效果[J]. 中国医药, 2019, 14(2): 208-211.
    李林静, 李华旭, 闫东星, 等. N-乙酰半胱氨酸联合有氧运动对慢性阻塞性肺疾病稳定期患者肺功能、生活质量及血清氧化因子的影响[J]. 新乡医学院学报, 2018, 29(12): 1208-1210.
    盖红梅, 包红, 但淑杰. 噻托溴铵粉吸入剂联合呼吸训练对稳定期慢性阻塞性肺疾病的疗效观察[J]. 山西医药杂志, 2018, 47(24): 8-11.
    叶雪丹, 王君, 陆园园, 等. 辛伐他汀联合噻托溴铵治疗慢性阻塞性肺病合并肺动脉高压的临床研究[J]. 中国临床药理学杂志, 2019, 35(9): 8-10.
    王芳. 六君子丸联合噻托溴铵治疗慢性阻塞性肺疾病稳定期的临床研究[J]. 现代药物与临床, 2019, 34(11): 3265-3270.
    刘振坤, 乔明涛, 安瑞肖, 等. 川贝枇杷胶囊联合噻托溴铵治疗慢性阻塞性肺疾病急性加重期的临床研究[J]. 现代药物与临床, 2019, 25(18): 963-965.
    薛佩妮, 冯敏娟, 王惠琴. 噻托溴铵粉联合糖皮质激素治疗慢性阻塞性肺疾病疗效及对患者生活质量评分的影响[J]. 陕西医学杂志, 2020, 2(8): 165-168.
    秦茵茵, 高国英, 谢晓鸿, 等. 噻托溴铵对慢性阻塞性肺疾病患者呼吸中枢驱动影响的临床研究[J]. 中国实用内科杂志, 2018, 38(11): 1086-1089.
  • Cited by

    Periodical cited type(10)

    1. 李慧. 全身麻醉联合硬膜外麻醉在直肠癌手术患者中的应用. 中国肛肠病杂志. 2024(07): 32-34 .
    2. 赵丽丽,郑城厚,郑长丽. 全身麻醉复合硬膜外腔阻滞麻醉对腹部手术患者应激反应及术后恢复的影响. 系统医学. 2024(22): 16-19+24 .
    3. 王琳,刘冰,刘国华,杨邯平. 抵抗素基因多态性与结直肠癌易感性的相关性. 实用临床医药杂志. 2023(02): 50-54 . 本站查看
    4. 金丽. 胸椎旁神经阻滞复合全身麻醉在腹腔镜大肠癌手术中的应用效果观察. 中国肛肠病杂志. 2023(01): 21-23 .
    5. 韦惠,谭新梅,蓝英年. 超声引导竖脊肌阻滞在开胸手术中的临床应用. 中国急救复苏与灾害医学杂志. 2023(09): 1206-1210 .
    6. 杨明宝. 硬膜外麻醉复合全麻对结直肠癌手术患者组织氧合、麻醉用药剂量的影响分析. 黑龙江医学. 2023(18): 2225-2228 .
    7. 郭健,孙文华,董传令. 腹横肌平面阻滞和局部浸润麻醉对腹部手术患者麻醉效果和安全性的影响. 中国药物滥用防治杂志. 2023(10): 1710-1713 .
    8. 吴海英,于红霞. 经腹超声检查对结直肠癌化疗患者伴转移的诊断价值. 中国肛肠病杂志. 2023(10): 5-8 .
    9. 孙磊. 全身麻醉联合硬膜外麻醉在腹腔镜下直肠癌根治术中的效果. 中外医学研究. 2023(33): 113-117 .
    10. 唐志明,吴盼,黄兴强. 全身麻醉复合罗哌卡因腹横肌平面神经阻滞用于腹腔镜手术中的价值分析. 中外医学研究. 2022(33): 118-122 .

    Other cited types(1)

Catalog

    Article views (363) PDF downloads (10) Cited by(11)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return